{"id":58729,"date":"2024-01-17T10:01:06","date_gmt":"2024-01-17T09:01:06","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/u-s-patent-office-invalidates-seagen-patent-in-dispute-between-daiichi-sankyo-and-seagen\/"},"modified":"2024-01-17T10:01:06","modified_gmt":"2024-01-17T09:01:06","slug":"u-s-patent-office-invalidates-seagen-patent-in-dispute-between-daiichi-sankyo-and-seagen","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/u-s-patent-office-invalidates-seagen-patent-in-dispute-between-daiichi-sankyo-and-seagen\/","title":{"rendered":"U.S. Patent Office Invalidates Seagen Patent in Dispute between Daiichi Sankyo and Seagen"},"content":{"rendered":"
\n

TOKYO & BASKING RIDGE, N.J.–(BUSINESS WIRE)–Daiichi Sankyo Co., Ltd. (TSE: 4568) (hereinafter, Daiichi Sankyo) announced today that the U.S. Patent and Trademark Office (U.S. PTO) rendered a Final Written Decision invalidating all claims of Seagen Inc.\u2019s U.S. patent 10,808,039 (the \u2019039 patent) that were challenged by Daiichi Sankyo in a post-grant review proceeding (PGR).<\/p>\n

<\/a>
<\/a><\/p>\n

\n\u201cWe are pleased that the U.S. PTO invalidated all challenged claims of the \u2019039 patent,\u201d said Naoto Tsukaguchi, Corporate Officer and General Counsel, Daiichi Sankyo.<\/p>\n

\nOn December 23, 2020, Daiichi Sankyo filed a PGR petition with the U.S. PTO contesting the patentability of certain claims of the \u2019039 patent. On April 7, 2022, the U.S. PTO granted Daiichi Sankyo\u2019s request to institute the PGR.<\/p>\n

\nThe \u2019039 patent was the sole patent-in-suit in the infringement litigation between the parties in the U.S. District Court for the Eastern District of Texas, an appeal of which is now pending in the U.S. Court of Appeals for the Federal Circuit.<\/p>\n

\nAbout Daiichi Sankyo
\n
<\/b>Daiichi Sankyo is an innovative global healthcare company contributing to the sustainable development of society that discovers, develops, and delivers new standards of care to enrich the quality of life around the world. With more than 120 years of experience, Daiichi Sankyo leverages its world-class science and technology to create new modalities and innovative medicines for people with cancer, cardiovascular and other diseases with high unmet medical need. For more information, please visit www.daiichisankyo.com<\/a>.<\/p>\n

Contacts<\/b> <\/p>\n

\nMedia Contacts<\/b>:<\/p>\n

Global\/Japan:<\/b>
Koji Ogiwara
\n
Daiichi Sankyo Co., Ltd.
\n
ogiwara.koji.ay@daiichisankyo.co.jp<\/i><\/a>
+81 3 6225 1126 (office)<\/p>\n

US<\/b>
Kim Wix
\n
Daiichi Sankyo, Inc.
\n
kwix@dsi.com<\/i><\/a>
+1 908 992 6633<\/p>\n

Investor Relations Contact:<\/b>
DaiichiSankyoIR@daiichisankyo.co.jp<\/i><\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

TOKYO & BASKING RIDGE, N.J.–(BUSINESS WIRE)–Daiichi Sankyo Co., Ltd. (TSE: 4568) (hereinafter, Daiichi Sankyo) announced today that the U.S. Patent and Trademark Office (U.S. PTO) rendered a Final Written Decision invalidating all claims of Seagen Inc.\u2019s U.S. patent 10,808,039 (the \u2019039 patent) that were challenged by Daiichi Sankyo in a post-grant review proceeding (PGR). \u201cWe … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-58729","6":"format-standard","7":"category-industry"},"yoast_head":"\nU.S. Patent Office Invalidates Seagen Patent in Dispute between Daiichi Sankyo and Seagen - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/u-s-patent-office-invalidates-seagen-patent-in-dispute-between-daiichi-sankyo-and-seagen\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"U.S. Patent Office Invalidates Seagen Patent in Dispute between Daiichi Sankyo and Seagen - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"TOKYO & BASKING RIDGE, N.J.–(BUSINESS WIRE)–Daiichi Sankyo Co., Ltd. (TSE: 4568) (hereinafter, Daiichi Sankyo) announced today that the U.S. Patent and Trademark Office (U.S. PTO) rendered a Final Written Decision invalidating all claims of Seagen Inc.\u2019s U.S. patent 10,808,039 (the \u2019039 patent) that were challenged by Daiichi Sankyo in a post-grant review proceeding (PGR). \u201cWe ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/u-s-patent-office-invalidates-seagen-patent-in-dispute-between-daiichi-sankyo-and-seagen\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2024-01-17T09:01:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20240116137394\/en\/2001104\/21\/JPEG_Full_Color.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/u-s-patent-office-invalidates-seagen-patent-in-dispute-between-daiichi-sankyo-and-seagen\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/u-s-patent-office-invalidates-seagen-patent-in-dispute-between-daiichi-sankyo-and-seagen\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"U.S. Patent Office Invalidates Seagen Patent in Dispute between Daiichi Sankyo and Seagen\",\"datePublished\":\"2024-01-17T09:01:06+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/u-s-patent-office-invalidates-seagen-patent-in-dispute-between-daiichi-sankyo-and-seagen\\\/\"},\"wordCount\":290,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/u-s-patent-office-invalidates-seagen-patent-in-dispute-between-daiichi-sankyo-and-seagen\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20240116137394\\\/en\\\/2001104\\\/21\\\/JPEG_Full_Color.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/u-s-patent-office-invalidates-seagen-patent-in-dispute-between-daiichi-sankyo-and-seagen\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/u-s-patent-office-invalidates-seagen-patent-in-dispute-between-daiichi-sankyo-and-seagen\\\/\",\"name\":\"U.S. Patent Office Invalidates Seagen Patent in Dispute between Daiichi Sankyo and Seagen - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/u-s-patent-office-invalidates-seagen-patent-in-dispute-between-daiichi-sankyo-and-seagen\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/u-s-patent-office-invalidates-seagen-patent-in-dispute-between-daiichi-sankyo-and-seagen\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20240116137394\\\/en\\\/2001104\\\/21\\\/JPEG_Full_Color.jpg\",\"datePublished\":\"2024-01-17T09:01:06+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/u-s-patent-office-invalidates-seagen-patent-in-dispute-between-daiichi-sankyo-and-seagen\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/u-s-patent-office-invalidates-seagen-patent-in-dispute-between-daiichi-sankyo-and-seagen\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/u-s-patent-office-invalidates-seagen-patent-in-dispute-between-daiichi-sankyo-and-seagen\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20240116137394\\\/en\\\/2001104\\\/21\\\/JPEG_Full_Color.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20240116137394\\\/en\\\/2001104\\\/21\\\/JPEG_Full_Color.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/u-s-patent-office-invalidates-seagen-patent-in-dispute-between-daiichi-sankyo-and-seagen\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"U.S. Patent Office Invalidates Seagen Patent in Dispute between Daiichi Sankyo and Seagen\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"U.S. Patent Office Invalidates Seagen Patent in Dispute between Daiichi Sankyo and Seagen - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/u-s-patent-office-invalidates-seagen-patent-in-dispute-between-daiichi-sankyo-and-seagen\/","og_locale":"en_US","og_type":"article","og_title":"U.S. Patent Office Invalidates Seagen Patent in Dispute between Daiichi Sankyo and Seagen - Pharma Trend","og_description":"TOKYO & BASKING RIDGE, N.J.–(BUSINESS WIRE)–Daiichi Sankyo Co., Ltd. (TSE: 4568) (hereinafter, Daiichi Sankyo) announced today that the U.S. Patent and Trademark Office (U.S. PTO) rendered a Final Written Decision invalidating all claims of Seagen Inc.\u2019s U.S. patent 10,808,039 (the \u2019039 patent) that were challenged by Daiichi Sankyo in a post-grant review proceeding (PGR). \u201cWe ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/u-s-patent-office-invalidates-seagen-patent-in-dispute-between-daiichi-sankyo-and-seagen\/","og_site_name":"Pharma Trend","article_published_time":"2024-01-17T09:01:06+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20240116137394\/en\/2001104\/21\/JPEG_Full_Color.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/u-s-patent-office-invalidates-seagen-patent-in-dispute-between-daiichi-sankyo-and-seagen\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/u-s-patent-office-invalidates-seagen-patent-in-dispute-between-daiichi-sankyo-and-seagen\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"U.S. Patent Office Invalidates Seagen Patent in Dispute between Daiichi Sankyo and Seagen","datePublished":"2024-01-17T09:01:06+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/u-s-patent-office-invalidates-seagen-patent-in-dispute-between-daiichi-sankyo-and-seagen\/"},"wordCount":290,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/u-s-patent-office-invalidates-seagen-patent-in-dispute-between-daiichi-sankyo-and-seagen\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20240116137394\/en\/2001104\/21\/JPEG_Full_Color.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/u-s-patent-office-invalidates-seagen-patent-in-dispute-between-daiichi-sankyo-and-seagen\/","url":"https:\/\/pharma-trend.com\/en\/u-s-patent-office-invalidates-seagen-patent-in-dispute-between-daiichi-sankyo-and-seagen\/","name":"U.S. Patent Office Invalidates Seagen Patent in Dispute between Daiichi Sankyo and Seagen - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/u-s-patent-office-invalidates-seagen-patent-in-dispute-between-daiichi-sankyo-and-seagen\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/u-s-patent-office-invalidates-seagen-patent-in-dispute-between-daiichi-sankyo-and-seagen\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20240116137394\/en\/2001104\/21\/JPEG_Full_Color.jpg","datePublished":"2024-01-17T09:01:06+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/u-s-patent-office-invalidates-seagen-patent-in-dispute-between-daiichi-sankyo-and-seagen\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/u-s-patent-office-invalidates-seagen-patent-in-dispute-between-daiichi-sankyo-and-seagen\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/u-s-patent-office-invalidates-seagen-patent-in-dispute-between-daiichi-sankyo-and-seagen\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20240116137394\/en\/2001104\/21\/JPEG_Full_Color.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20240116137394\/en\/2001104\/21\/JPEG_Full_Color.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/u-s-patent-office-invalidates-seagen-patent-in-dispute-between-daiichi-sankyo-and-seagen\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"U.S. Patent Office Invalidates Seagen Patent in Dispute between Daiichi Sankyo and Seagen"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/58729","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=58729"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/58729\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=58729"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=58729"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=58729"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}